NewEdge Advisors’s Coherus Oncology CHRS Stock Holding History

NewEdge Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-300	Closed	-$717	–	3833
2024 Q1	$717	Hold	300	–	–	﹤0.01%	3547
2023 Q4	$999	Buy	+300	New	+$804	﹤0.01%	3466

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NewEdge Advisors's CHRS Position: Q2 2024 in Review

NewEdge Advisors sold out of Coherus Oncology (CHRS) in Q2 2024, closing a stake of 300 shares — an estimated $717 sold.

NewEdge Advisors first reported a position in CHRS in Q4 2023 and held it in 2 quarters. The position peaked at $999 in Q4 2023. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

NewEdge Advisors reported no remaining Coherus Oncology position as of Q2 2024 after selling out during the quarter.
NewEdge Advisors sold 300 Coherus Oncology shares in Q2 2024, an estimated $717.
NewEdge Advisors first reported a position in Coherus Oncology in Q4 2023 and held it in 2 quarters.
NewEdge Advisors's Coherus Oncology position peaked at $999 in Q4 2023.
135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on NewEdge Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.